Recent Press Releases

Actavis Confirms Generic Multaq® Patent Challenge

Actavis Confirms Generic Multaq® Patent Challenge Date(s): Feb. 28, 2014 8:00 AM DUBLIN, Feb. 28, 2014 /PRNewswire/ -- Actavis plc (NYSE: ACT) today confirmed that it has filed an Abbreviated New...

Teva Launches ADASUVE® in U.S.

Teva Launches ADASUVE® in U.S. The first and only orally inhaled medicine for the acute treatment of agitation associated with schizophrenia or bipolar I disorder in adults Date(s): 3-Mar-2014...

Actavis Confirms Generic Colcrys® Patent Challenge

Actavis Confirms Generic Colcrys® Patent Challenge Date(s): Feb. 28, 2014 4:05 PM DUBLIN, Feb. 28, 2014 /PRNewswire/ -- Actavis plc (NYSE: ACT) today confirmed that it has filed an Abbreviated...

US FDA APPROVES BYDUREON® PEN (EXENATIDE EXTENDED-RELEASE FOR INJECTABLE SUSPENSION) FOR ONCE-WEEKLY TREATMENT OF ADULTS with TYPE 2 DIABETES

US FDA APPROVES BYDUREON® PEN (EXENATIDE EXTENDED-RELEASE FOR INJECTABLE SUSPENSION) FOR ONCE-WEEKLY TREATMENT OF ADULTS with TYPE 2 DIABETES 3 March 2014 AstraZeneca today announced that the US...

Drug shortages continue to pose patient safety risks and challenge providers, according to Premier, Inc. survey

Drug shortages continue to pose patient safety risks and challenge providers, according to Premier, Inc. survey Analysis finds shortages increased U.S. hospital costs by an average of $230 million...

Bayer continues successful course in anniversary year

Bayer continues successful course in anniversary year Dynamic development in the Life Science businesses, MaterialScience below expectations / Outstanding growth for recently launched...

Bayer to acquire Dihon Pharmaceutical Group Co., Ltd. in China

Bayer to acquire Dihon Pharmaceutical Group Co., Ltd. in China Transaction strengthens Consumer Care business and moves Bayer HealthCare to a leading OTC position in key growth country...

Mylan Fourth Quarter 2013 Adjusted Diluted EPS Increases 20% to $0.78 and Full Year Adjusted Diluted EPS Increases 12% to $2.89

Mylan Fourth Quarter 2013 Adjusted Diluted EPS Increases 20% to $0.78 and Full Year Adjusted Diluted EPS Increases 12% to $2.89 Provides 2014 Adjusted Diluted EPS Guidance Range of $3.25 - $3.60 and...

Endo Announces Shareholder Approval of its Acquisition of Paladin Labs

Endo Announces Shareholder Approval of its Acquisition of Paladin Labs MALVERN, Pa., Feb. 26, 2014 /PRNewswire/ -- Endo Health Solutions Inc. (NASDAQ: ENDP) ("Endo") today announced that,...

FDA approves Myalept to treat rare metabolic disease

FDA approves Myalept to treat rare metabolic disease On Feb. 24, 2014, the U.S. Food and Drug Administration approved Myalept (metreleptin for injection) as replacement therapy to treat the...

Lilly's Once-Weekly Dulaglutide Shows Non-Inferiority to Liraglutide in Head-to-Head Phase III Trial for Type 2 Diabetes

Once-Weekly Dulaglutide Hits Primary Endpoint in Sixth Consecutive AWARD Trial

INDIANAPOLIS, Feb.

Ventana Medical Systems, Inc., Convenes International Patient Safety Advisory Board To Advance Standard Of Care And Reduce Risk Of Misdiagnosis

TUCSON, Ariz., Feb. 25, 2014 /PRNewswire/ -- Ventana Medical Systems, Inc.

NICE recommendation set to leave patients with newly diagnosed advanced melanoma without access to Yervoy® (ipilimumab)

NICE recommendation set to leave patients with newly diagnosed advanced melanoma without access to Yervoy® (ipilimumab) - Draft guidance effectively denies access to ipilimumab for NHS patients...

Almac adds simple solutions to bridge the gap between clinical and commercial packaging

Almac adds simple solutions to bridge the gap between clinical and commercial packaging Addressing client demand to ease the transition between clinical and commercial launch for blister...

Moody's: AbbVie, Amgen and Roche most exposed to biosimilar drugs market

Moody's: AbbVie, Amgen and Roche most exposed to biosimilar drugs market Global Credit Research - 25 Feb 2014 New York, February 25, 2014 -- Companies are racing to expand the global biosimilar...

NICE consults on draft guidance recommending new drug for type 2 diabetes

NICE consults on draft guidance recommending new drug for type 2 diabetes NICE, the health and social care guidance body, is currently appraising canagliflozin (Invokana, Janssen-Cilag) when used in...

Novartis shareholders approve all resolutions proposed by Novartis Board of Directors

Novartis shareholders approve all resolutions proposed by Novartis Board of Directors - Shareholders approve 17th consecutive dividend increase to CHF 2.45 (+7%) per share for 2013, representing a...

Public Citizen Petitions FDA for a Black Box Warning on Testosterone Products

Public Citizen Petitions FDA for a Black Box Warning on Testosterone Products More Than 5 Million Prescriptions Were Filled Last Year; Products Are Associated With Heart Attacks and Other...

Iroko Pharmaceuticals Receives FDA Approval for TIVORBEX™

Iroko Pharmaceuticals Receives FDA Approval for TIVORBEX™ New Lower Dose NSAID Marks Iroko's Second FDA Approval in Approximately Four Months PHILADELPHIA, FEBRUARY 24, 2014 — Iroko...